
June 17 (Reuters) - Mineralys Therapeutics Inc MLYS.O:
MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 EXPLORE-CKD TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION IN SUBJECTS WITH CKD AND ALBUMINURIA
MINERALYS THERAPEUTICS INC - LORUNDROSTAT DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE
MINERALYS THERAPEUTICS INC - SERIOUS ADVERSE EVENTS REPORTED IN 3% OF SUBJECTS DURING LORUNDROSTAT TREATMENT
MINERALYS THERAPEUTICS INC - LORUNDROSTAT 25 MG ACHIEVES 9.3 MMHG REDUCTION IN SYSTOLIC BLOOD PRESSURE
MINERALYS THERAPEUTICS INC - LORUNDROSTAT SHOWS 31% REDUCTION IN URINE ALBUMIN-TO-CREATININE RATIO
MINERALYS THERAPEUTICS INC - ONE SUBJECT DISCONTINUED LORUNDROSTAT DUE TO ELEVATED POTASSIUM